Analysis of CD34 populations in mobilised peripheral blood stem cell harvests and in bone marrow by fluorescent in situ hybridisation for the bcr ablgene fusion in patients with chronic granulocytic leukaemia

For those patients ineligible for allogeneic bone marrow transplant and who are non-responsive to interferon, autotransplant with peripheral blood ste m cells (PBSC) mobilised after intensive chemotherapy, may provide a novel approach to improve prognosis in patients with chronic granulocytic leukaem ia. PBSC harvests are assessed for CD84-positive cell numbers, which serve as an indicator of engraftment potential, and are also analysed cytogenetic ally to ascertain tumour cell contamination. However, a more accurate asses sment of PBSC harvest contamination requires investigation of the Philadelp hia (Ph) status of the CD34(pos) population, in which the cells that provid e long-term engraftment are contained. In this study, we have analysed thes e levels in mobilised PBSC and also in bone marrow (BM) harvests, taken sev eral weeks prior to mobilising chemotherapy. Using fluorescent in situ hybr idisation for the bcr/abl gene fusion, we have shown that the median number of Ph negative cells in CD34(pos) isolated populations was 14.95% in BM co mpared to 79.05% in PBSC harvests and that in all PBSC samples tested, Ph p ositivity in CD34(pos) populations was always detectable either by FISH or one round PCR methods. In paired assessments of both PBSC and BM harvests, higher levels of Ph negative CD34(pos) cells (greater than or equal to 14%) isolated from BM harvests, taken prior to intensive chemotherapy, correlat ed with higher levels of Ph negative CD34(pos) cells (greater than or equal to 78.5%) in PBSC harvests. These data may aid in the selection of patient s for whom PBSC harvesting, after mobilisation, is more likely to achieve a n autograft product containing predominantly Ph negative CD34(pos) cells an d may exclude those patients for whom the risk, morbidity and expense of st em cell harvesting may have no apparent benefit over a chronic phase BM har vest.